Business
RedHill raises USD 19.4m to fund acquisition hunt amid cash crunch
Israel-based RedHill Biopharma Ltd. (Nasdaq: RDHL) announced a private placement of ADSs and accompanying warrants with potential gross proceeds of up to...
Sanofi backs Cour's nanoparticle therapy for type 1 diabetes in USD 50m Series B
Skokie, Illinois-based COUR Pharma has closed a USD 50 million Series B financing round to advance CNP-103, its lead nanoparticle-based immune tolerance...
cAMPfield launches with USD 180m to challenge oral IBD therapy's tolerability barrier
San Diego-based cAMPfield Therapeutics, Inc. has launched with a USD 180 million Series A financing to advance prifemilast (HY1999/HPP737), a once-daily...
Acumen secures exclusive Alzheimer's license for JCR's brain-penetrating antibody platform
Acumen Pharmaceuticals (Nasdaq: ABOS) has exercised its exclusive option under its collaboration with Japan-based JCR Pharmaceuticals Co., Ltd. (TSE: 4552),...
Spot Biosystems emerges from stealth with USD 40 million, early human data for non-viral dystrophin delivery
Palo Alto-based Spot Biosystems has emerged from stealth with USD 40 million in venture financing and early clinical data suggesting its extracellular...
Legend Bio raises USD 226 million to fund pipeline as CARVYKTI sales accelerate toward 2026 profitability
Bridgewater, New Jersey-based Legend Biotech Corporation (Nasdaq: LEGN) announced the pricing of an underwritten public offering of American Depositary...
LG Chem bets on AI-designed antibodies to solve solid tumor toxicity problem
South Korea-based LG Chem (KRX: 051910) has agreed to fund discovery of a tumour-selective multispecific antibody through UK-based LabGenius Therapeutics,...
D&D Pharmatech pairs oral peptide platform with LG's generative AI to accelerate drug discovery
D&D Pharmatech (KOSDAQ: 347850), whose oral peptide delivery platform has attracted over USD 7 billion in downstream pharma acquisitions, has signed a...
Biogen accelerates immunology pivot with USD 1 billion RayThera acquisition
Biogen (Nasdaq: BIIB) has agreed to acquire San Diego-based RayThera Inc. for up to USD 1 billion, adding a portfolio of small molecule anti-inflammatory...
Kardigan prices up IPO for at least USD 400m on cardiac myosin inhibitor pedigree
Kardigan, Inc. (Nasdaq: KARD), a clinical-stage precision cardiovascular company whose three in-licensed drug candidates target indications with no approved...
Jazz bets USD 56m on AbCellera's T-cell engagers for solid tumors
Jazz Pharmaceuticals (Nasdaq: JAZZ) has committed USD 56 million upfront to access AbCellera Biologics' (Nasdaq: ABCL) T-cell engaging multispecific...
Gero raises USD 17m to advance AI-driven aging drug discovery platform
Singapore-based Gero, a physics-first AI drug discovery company focused on age-related disease, has announced USD 17 million in new equity financing,...
MultiValent launches with USD 27.4m to advance dual-target prostate cancer conjugate into clinic
Los Altos, California-based MultiValent Biotherapies, Inc. has closed a USD 27.425 million first closing of its Series A Preferred Stock financing to...
Dyne secures USD 400m debt facility to fund dual neuromuscular launches without dilution
Waltham, Massachusetts-based Dyne Therapeutics, Inc. (Nasdaq: DYN) announced an amendment to its existing non-dilutive senior secured term loan facility...
Vedana launches with USD 46 million to challenge CGRP monopoly in migraine prevention
Seattle-based Vedana Therapeutics has launched from stealth with a USD 46 million Series A financing round to advance a portfolio of antibody-based...
The AllSci Brief
Systematic R&D and deal news. Daily.